Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)-RFA-PS-22-001, Implementing Pre-Exposure Prophylaxis for HIV Prevention in Syringe Service Programs; RFA-PS-22-002, Implementation Research on Telehealth Strategies To Support Retention in Care and Treatment Among Antiretroviral Therapy (ART) Patients and Pre-Exposure Prophylaxis (PrEP) Clients and RFA-PS-22-004, Understanding HIV/STD Risk and Enhancing PrEP Implementation Messaging in a Diverse Community-Based Sample of Gay, Bisexual, and Other Men Who Have Sex With Men in a Transformational Era; Amended Notice of Meeting, 9362 [2022-03555]

Download as PDF 9362 Federal Register / Vol. 87, No. 34 / Friday, February 18, 2022 / Notices jspears on DSK121TN23PROD with NOTICES1 This RFI is for planning purposes only and should not be construed as a policy, solicitation for applications, or as an obligation on the part of the Government to provide support for any ideas identified in response to it. AHRQ will use the information submitted in response to this RFI at its discretion and will not provide comments to any responder’s submission. However, responses to the RFI may be reflected in future solicitation(s) or policies. The information provided will be analyzed and may appear in reports. Respondents will not be identified in any published reports. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. No proprietary, classified, confidential, or sensitive information should be included in your response. The contents of all submissions will be made available to the public upon request. Materials submitted must be publicly available or able to be made public. Collaborative: Using Data to Promote the Health and Wellness of People with Disabilities. Date: May 3, 2022. Time: 11:00 a.m.–6:00 p.m., EDT. Place: Teleconference. Agenda: To review and evaluate grant applications. For Further Information Contact: Jaya Raman, Ph.D., Scientific Review Officer, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway, Mailstop S107– B, Atlanta, Georgia 30341, Telephone: (770) 488–6511, Email: JRaman@ cdc.gov. The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Dated: February 15, 2022. Marquita Cullom, Associate Director. Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2022–03551 Filed 2–17–22; 8:45 am] [FR Doc. 2022–03554 Filed 2–17–22; 8:45 am] BILLING CODE 4160–90–P BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Centers for Disease Control and Prevention Notice of Closed Meeting Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—RFA–PS–22– 001, Implementing Pre-Exposure Prophylaxis for HIV Prevention in Syringe Service Programs; RFA–PS– 22–002, Implementation Research on Telehealth Strategies To Support Retention in Care and Treatment Among Antiretroviral Therapy (ART) Patients and Pre-Exposure Prophylaxis (PrEP) Clients and RFA–PS–22–004, Understanding HIV/STD Risk and Enhancing PrEP Implementation Messaging in a Diverse CommunityBased Sample of Gay, Bisexual, and Other Men Who Have Sex With Men in a Transformational Era; Amended Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)— SIP22–004, Disability and Health Data VerDate Sep<11>2014 18:54 Feb 17, 2022 Jkt 256001 Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP) RFA–PS– 22–001, Implementing Pre-exposure Prophylaxis for HIV Prevention in Syringe Service Programs; RFA–PS–22– 002, Implementation Research on PO 00000 Frm 00056 Fmt 4703 Sfmt 9990 Telehealth Strategies to support Retention in Care and Treatment among Antiretroviral Therapy (ART) Patients and Pre-exposure Prophylaxis (PrEP) Clients; and RFA–PS–22–004, Understanding HIV/STD Risk and Enhancing PrEP Implementation Messaging in a Diverse CommunityBased Sample of Gay, Bisexual, and Other Men Who Have Sex with Men in a Transformational Era. Date: March 30, 2022. Time: 10:00 a.m.–5:00 p.m. (EDT). Place: Teleconference. The meeting was published in the Federal Register on February 4, 2022, Volume 87, Number 24, page 6562– 6563. The meeting is being amended to remove RFA–PS–22–002, Implementation Research on Telehealth Strategies to Support Retention in Care and Treatment among Antiretroviral Therapy (ART) Patients and Preexposure Prophylaxis (PrEP) Clients and should read as follows: RFA–PS–22–001, Implementing Preexposure Prophylaxis for HIV Prevention in Syringe Service Programs and RFA–PS–22–004, Understanding HIV/STD Risk and Enhancing PrEP Implementation Messaging in a Diverse Community-Based Sample of Gay, Bisexual, and Other Men Who Have Sex with Men in a Transformational Era. The meeting is closed to the public. For Further Information Contact: Gregory Anderson, M.S., M.P.H., Scientific Review Officer, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC, 1600 Clifton Road NE, Mailstop US8–1, Atlanta, Georgia 30329, Telephone: (404) 718– 8833, Email: GAnderson@cdc.gov. The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2022–03555 Filed 2–17–22; 8:45 am] BILLING CODE 4163–18–P E:\FR\FM\18FEN1.SGM 18FEN1

Agencies

[Federal Register Volume 87, Number 34 (Friday, February 18, 2022)]
[Notices]
[Page 9362]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-03555]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel (SEP)--RFA-PS-22-001, Implementing Pre-Exposure 
Prophylaxis for HIV Prevention in Syringe Service Programs; RFA-PS-22-
002, Implementation Research on Telehealth Strategies To Support 
Retention in Care and Treatment Among Antiretroviral Therapy (ART) 
Patients and Pre-Exposure Prophylaxis (PrEP) Clients and RFA-PS-22-004, 
Understanding HIV/STD Risk and Enhancing PrEP Implementation Messaging 
in a Diverse Community-Based Sample of Gay, Bisexual, and Other Men Who 
Have Sex With Men in a Transformational Era; Amended Notice of Meeting

    Notice is hereby given of a change in the meeting of the Disease, 
Disability, and Injury Prevention and Control Special Emphasis Panel 
(SEP) RFA-PS-22-001, Implementing Pre-exposure Prophylaxis for HIV 
Prevention in Syringe Service Programs; RFA-PS-22-002, Implementation 
Research on Telehealth Strategies to support Retention in Care and 
Treatment among Antiretroviral Therapy (ART) Patients and Pre-exposure 
Prophylaxis (PrEP) Clients; and RFA-PS-22-004, Understanding HIV/STD 
Risk and Enhancing PrEP Implementation Messaging in a Diverse 
Community-Based Sample of Gay, Bisexual, and Other Men Who Have Sex 
with Men in a Transformational Era.

    Date: March 30, 2022.
    Time: 10:00 a.m.-5:00 p.m. (EDT).
    Place: Teleconference.
    The meeting was published in the Federal Register on February 4, 
2022, Volume 87, Number 24, page 6562-6563.
    The meeting is being amended to remove RFA-PS-22-002, 
Implementation Research on Telehealth Strategies to Support Retention 
in Care and Treatment among Antiretroviral Therapy (ART) Patients and 
Pre-exposure Prophylaxis (PrEP) Clients and should read as follows:
    RFA-PS-22-001, Implementing Pre-exposure Prophylaxis for HIV 
Prevention in Syringe Service Programs and RFA-PS-22-004, Understanding 
HIV/STD Risk and Enhancing PrEP Implementation Messaging in a Diverse 
Community-Based Sample of Gay, Bisexual, and Other Men Who Have Sex 
with Men in a Transformational Era.
    The meeting is closed to the public.
    For Further Information Contact: Gregory Anderson, M.S., M.P.H., 
Scientific Review Officer, National Center for HIV, Viral Hepatitis, 
STD, and TB Prevention, CDC, 1600 Clifton Road NE, Mailstop US8-1, 
Atlanta, Georgia 30329, Telephone: (404) 718-8833, Email: 
[email protected].
    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention and 
the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2022-03555 Filed 2-17-22; 8:45 am]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.